• The Issue Panel at the ISPOR European Congress in Glasgow on 6 November ‘Value Added Medicines: Time to Adjust the Health Technology Assessment Decision Frameworks?’ will debate how patients can benefit from value added medicines.
  • Value added medicines are medicines which are based on 3 drug repurposing models: reformulation, repositioning or a combination of known molecules, which deliver substantial value for patients and society.
  • HTA decision-making in Europe presents challenges for full value added recognition of these medicines. Addressing ways to recognise patient-centric innovation in value assessment frameworks is crucial for the assessment of value added medicines.

Value added medicines represent a major opportunity to improve patients’ quality of life, health outcomes or adherence, and to address a number of medicine-related healthcare inefficiencies, improving healthcare provision and organisation while contributing to the sustainability of healthcare systems.

To ensure access to value added medicines for patients, the Value Added Medicines Group, a sector group of Medicines for Europe, will participate in the ISPOR 20th Annual European Congress  on an Issue Panel entitled “Value Added Medicines: Time To Adjust The Health Technology Assessment Decision Frameworks?”.

Moderated by Professor Michael Drummond (Professor of Health Economics at the Univerity of York), the panellists (Professor Mondher Toumi from the Public Health Department of Aix-Marseille University, Professor Ulf Persson from the Swedish Institute of Health Economics and Luigi Burgio – Head of Market Access Teva Italy and Chairman of the HTA Working Group at Medicines for Europe) will debate current challenges for capturing the benefits of value added medicines as well as key recommendations to integrate and recognise patient-centric innovation in HTA decision frameworks.

Umberto Comberiati, the Chairman of the Value Added Medicines Group,: “The time has come to explore new areas to deliver better health and access for patients, tapping into a sustainable source of patient-centric innovation. Value added medicines are an opportunity to deliver benefits to patients, payers and healthcare systems. However, there is a challenge to ensure that benefits can be appropriately assessed  via HTA decision frameworks. The ISPOR Issue Panel will allow an informed debate among experts, industry and stakeholders.

Medicines for Europe invites you to join the ISPOR European Congress in Glasgow and please follow us on Twitter and LinkedIn to know more about how European patients can better benefit from value added medicines. More information on the Issue Panel and the challenges and recommendations on adjusted HTA decision frameworks for value added medicines can be found here.